KRAS
KRAS is a human gene, formally the KRAS proto-oncogene, GTPase, and also known as Kirsten rat sarcoma viral oncogene homolog.
KRAS is a human gene, formally the KRAS proto-oncogene, GTPase, and also known as Kirsten rat sarcoma viral oncogene homolog. It encodes a small GTPase of the RAS family, a membrane-associated protein that cycles between an inactive GDP-bound state and an active GTP-bound state. This switch is controlled by guanine nucleotide exchange factors such as SOS1, which load GTP onto KRAS, and by GTPase-activating proteins that accelerate GTP hydrolysis. In its active conformation, KRAS transmits signals from upstream receptor tyrosine kinases, including the EGFR family, to downstream effectors, most prominently the RAF–MEK–ERK (MAPK) cascade and the Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) pathway, thereby regulating cell proliferation, differentiation, and survival. The protein requires prenylation and membrane localization for activity, and alternative splicing produces the K-Ras4A and K-Ras4B isoforms.
Somatic missense mutations in KRAS, typically at codons 12, 13, and 61, impair GTP hydrolysis and lock the protein in a constitutively active state, driving sustained MAPK and PI3K/AKT signaling. KRAS is among the most frequently mutated oncogenes in human cancer, with the highest prevalence in pancreatic ductal adenocarcinoma and substantial involvement in colorectal cancer, lung adenocarcinoma, and appendiceal adenocarcinoma; co-occurring alterations in TP53, STK11, KEAP1, and PIK3CA further shape tumor behavior and clinical outcomes. Long considered undruggable, KRAS is now addressed by several therapeutic strategies: covalent inhibitors of the KRAS G12C variant, pan-RAS inhibitors, allele-selective agents, SOS1 inhibitors that block nucleotide exchange, and targeted degraders built as proteolysis-targeting chimeras. Because resistance to single-agent KRAS inhibition arises rapidly — through reactivation of parallel signaling nodes, lineage plasticity, and upstream or orthogonal pathways involving EGFR, RAF1, and JAK2/STAT3 — combination regimens pairing KRAS-directed drugs with MEK inhibitors such as trametinib, PI3K inhibitors, or receptor tyrosine kinase inhibitors are an active focus of preclinical and clinical development. Genetically engineered mouse models carrying conditional Kras and TP53 alleles remain a standard system for studying KRAS-driven tumorigenesis and treatment response.
Where the papers sit
47 papers from the last 6 months study KRAS directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 4 observational · 8 human data · 27 preclinical · 8 unclassified
Themes one subject · 1 paradigm shift · 1 new direction
Those 47 are all about one subject.
-
KRAS Disease Biology
Work centers on how KRAS alterations shape tumor growth, treatment response, and therapeutic vulnerability across cancers and inflammatory disease. Resistance is linked to interferon signaling, CASTOR1 loss, and tumor context, while immune approaches include mutant p53–SPP1 modulation and TCR engagers. Drug development ranges from KRASG12C and KRASG12D inhibitors and CRBN degraders to daraxonrasib combinations and fluvoxamine repurposing. Computational prediction, multi-omics models, and phytochemical studies broaden the search, but no single strategy dominates.
KRAS-mutant tumors can be intrinsically resistant to KRAS inhibition because non-KRAS signaling states determine drug response
The pancreatic-cancer study of KRASG12D-mutant patient-derived organoids and the KRASG12D-driven NSCLC study of CASTOR1-deficient mice and tumor organoids separately show that KRAS mutation does not guarantee dependence on KRAS inhibition. In pancreatic cancer, suppressed interferon signaling associated with sustained MYC activity produces intrinsic resistance, which can be reversed by interferon-β; in NSCLC, CASTOR1 loss activates mTORC1 and related AKT/ERK signaling, with resistance overcome by cotargeting mTORC1 or PI3K/mTOR 42956743Oct 42913021Oct. The resulting change is from treating the KRAS allele as a sufficient predictor of response to treating tumor state and bypass circuitry as determinants requiring biomarker-guided combination therapy.
KRAS functions as an immunometabolic regulator of pathogenic TH17 cells in autoimmune disease
Autoimmune uveitis and experimental uveitis and colitis models treated with fluvoxamine show that GPR183-driven SOS-dependent KRAS activation in pathogenic CD4+ T cells promotes copper-overload mitochondrial stress, glycolytic rewiring, and TH17 pathogenicity, rather than serving only as a cancer-associated oncogenic driver or therapeutic target. Blocking this pathway with the GPR183 antagonist fluvoxamine attenuated disease, placing KRAS within an autoimmune immunometabolic mechanism and identifying a repurposing strategy for uveitis 42950033Oct.
Papers
The 47 papers from the last 6 months that study KRAS directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
KRAS Disease Biology (47)
- Random forest approach to predict genes correlated with adaptive responses to KRASG12C inhibitor. PloS one · 11 Nov 2026 PMID 43013488
- KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. Cancer cell · 29 Oct 2026 PMID 42956743
- Intrinsic resistance to KRAS inhibition: Interfering with interferon. Cancer cell · 29 Oct 2026 PMID 42956741
- Lipid-sensing GPR183-KRAS signaling mediates TH17 autoimmunity and identifies fluvoxamine repurposing in uveitis. Science advances · 28 Oct 2026 PMID 42950033
- Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
- CASTOR1 functional inactivation drives KRAS-mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression. Science advances · 23 Oct 2026 PMID 42913021
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
- Exploring the cytotoxic potential of Artemisia herba-alba crude extract and key phytoconstituents using in vitro assays and molecular docking insights. PloS one · 25 Sept 2026 PMID 42789608
- Proteomic regulation of anti-proliferative and anti-migratory activity by potent phytochemicals from Pistacia integerrima J.L. Steward Ex Brandis via PI3K, AKT1, and KRAS for Lung Cancer. Molecular biology reports · 12 Sept 2026 PMID 42730982
- Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
- MCKG-SL: Knowledge graph-based multi-feature cross-aggregation synthetic lethality prediction for KRAS gene. Artificial intelligence in medicine · 10 Sept 2026 PMID 42721585
- Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
- TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
- KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors. Science advances · 2 Sept 2026 PMID 42685218
- Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. Anticancer research · 31 Aug 2026 PMID 42674713
- Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
- One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
- Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer. Apoptosis : an international journal on programmed cell death · 20 Aug 2026 PMID 42622908
- Identification of a three-gene prognostic signature associated with tumor immune characteristics in lung adenocarcinoma: A comprehensive analysis of multi-omics data. Translational oncology · 17 Aug 2026 PMID 42607524
- Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study. Lung cancer (Amsterdam, Netherlands) · 17 Aug 2026 PMID 42607379
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
- Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles. Journal of controlled release : official journal of the Controlled Release Society · 11 Aug 2026 PMID 42580447
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
- KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles' Heel in Pancreatic Cancer. Cancer research · 15 Jul 2026 PMID 42452976
- Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors. Journal of medicinal chemistry · 14 Jul 2026 PMID 42446418
- An Iridium(III) Complex Induces Immunogenic Methuosis and Reprograms Tumor-Associated Macrophages for Chemoimmunotherapy against KRAS-Mutated Tumors. Journal of medicinal chemistry · 12 Jul 2026 PMID 42437351
- Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy. BMC cancer · 3 Jul 2026 PMID 42399819
- KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. Journal of hematology & oncology · 3 Jul 2026 PMID 42393724
- Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma. The Journal of clinical investigation · 1 Jul 2026 PMID 42383354
- Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer. Advances in therapy · 30 Jun 2026 PMID 42377736
- High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377115
- Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. Cancer discovery · 22 Jun 2026 PMID 42329102
- The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer cell · 11 Jun 2026 PMID 42276046
- Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses. Clinical cancer research : an official journal of the American Association for Cancer Research · 10 Jun 2026 PMID 42268349
- Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
- KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones. Cancer research · 8 Jun 2026 PMID 42258763
- Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy. Angewandte Chemie (International ed. in English) · 7 Jun 2026 PMID 42251661
- Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of medicinal chemistry · 5 Jun 2026 PMID 42247371
- The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation. Oncotarget · 3 Jun 2026 PMID 42233520
- A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences of the United States of America · 1 Jun 2026 PMID 42224594
- Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research · 27 May 2026 PMID 42200804
- Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European journal of cancer (Oxford, England : 1990) · 26 May 2026 PMID 42190397
- Navigating high-order protein fitness landscapes via deep learning on directed evolution trajectories. Proceedings of the National Academy of Sciences of the United States of America · 26 May 2026 PMID 42190010
- Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer cell · 21 May 2026 PMID 42167227
- Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Developmental cell · 20 May 2026 PMID 42161274
By study type
Observational studies and case reports (4)
- Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
- Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study. Lung cancer (Amsterdam, Netherlands) · 17 Aug 2026 PMID 42607379
- High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377115
- Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
Human data, design not indexed (8)
- One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
- The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer cell · 11 Jun 2026 PMID 42276046
- Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses. Clinical cancer research : an official journal of the American Association for Cancer Research · 10 Jun 2026 PMID 42268349
- Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European journal of cancer (Oxford, England : 1990) · 26 May 2026 PMID 42190397
- Navigating high-order protein fitness landscapes via deep learning on directed evolution trajectories. Proceedings of the National Academy of Sciences of the United States of America · 26 May 2026 PMID 42190010
- Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
Preclinical: animal, cell and lab studies (27)
- Random forest approach to predict genes correlated with adaptive responses to KRASG12C inhibitor. PloS one · 11 Nov 2026 PMID 43013488
- KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. Cancer cell · 29 Oct 2026 PMID 42956743
- Intrinsic resistance to KRAS inhibition: Interfering with interferon. Cancer cell · 29 Oct 2026 PMID 42956741
- Lipid-sensing GPR183-KRAS signaling mediates TH17 autoimmunity and identifies fluvoxamine repurposing in uveitis. Science advances · 28 Oct 2026 PMID 42950033
- CASTOR1 functional inactivation drives KRAS-mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression. Science advances · 23 Oct 2026 PMID 42913021
- Exploring the cytotoxic potential of Artemisia herba-alba crude extract and key phytoconstituents using in vitro assays and molecular docking insights. PloS one · 25 Sept 2026 PMID 42789608
- Proteomic regulation of anti-proliferative and anti-migratory activity by potent phytochemicals from Pistacia integerrima J.L. Steward Ex Brandis via PI3K, AKT1, and KRAS for Lung Cancer. Molecular biology reports · 12 Sept 2026 PMID 42730982
- Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
- Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
- TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
- KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors. Science advances · 2 Sept 2026 PMID 42685218
- Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. Anticancer research · 31 Aug 2026 PMID 42674713
- Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer. Apoptosis : an international journal on programmed cell death · 20 Aug 2026 PMID 42622908
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
- Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles. Journal of controlled release : official journal of the Controlled Release Society · 11 Aug 2026 PMID 42580447
- KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles' Heel in Pancreatic Cancer. Cancer research · 15 Jul 2026 PMID 42452976
- Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors. Journal of medicinal chemistry · 14 Jul 2026 PMID 42446418
- An Iridium(III) Complex Induces Immunogenic Methuosis and Reprograms Tumor-Associated Macrophages for Chemoimmunotherapy against KRAS-Mutated Tumors. Journal of medicinal chemistry · 12 Jul 2026 PMID 42437351
- Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy. BMC cancer · 3 Jul 2026 PMID 42399819
- Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma. The Journal of clinical investigation · 1 Jul 2026 PMID 42383354
- Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. Cancer discovery · 22 Jun 2026 PMID 42329102
- KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones. Cancer research · 8 Jun 2026 PMID 42258763
- Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy. Angewandte Chemie (International ed. in English) · 7 Jun 2026 PMID 42251661
- Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of medicinal chemistry · 5 Jun 2026 PMID 42247371
- The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation. Oncotarget · 3 Jun 2026 PMID 42233520
- A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences of the United States of America · 1 Jun 2026 PMID 42224594
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer cell · 21 May 2026 PMID 42167227
Unclassified: not yet indexed with MeSH (8)
- Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
- MCKG-SL: Knowledge graph-based multi-feature cross-aggregation synthetic lethality prediction for KRAS gene. Artificial intelligence in medicine · 10 Sept 2026 PMID 42721585
- Identification of a three-gene prognostic signature associated with tumor immune characteristics in lung adenocarcinoma: A comprehensive analysis of multi-omics data. Translational oncology · 17 Aug 2026 PMID 42607524
- KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. Journal of hematology & oncology · 3 Jul 2026 PMID 42393724
- Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer. Advances in therapy · 30 Jun 2026 PMID 42377736
- Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research · 27 May 2026 PMID 42200804
- Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Developmental cell · 20 May 2026 PMID 42161274
Written from 47 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-14 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.